pre-IPO PHARMA

COMPANY OVERVIEW

Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. The Company's proprietary oral delivery technology – Peptelligence™ – has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development.


LOCATION

  • Boonton, NJ, USA

  • THERAPEUTIC AREAS

  • Infectious Disease
  • Women's Health

  • WEBSITE

    https://enterisbiopharma.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Oct 26, 2022

    Enteris BioPharma Presents Study of Ovarest Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide


    Oct 10, 2022

    SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics


    Sep 12, 2022

    Enteris BioPharma Publishes White Paper Examining Factors to Consider While Evaluating Oral Administration of Peptides


    Aug 3, 2022

    Enteris BioPharma Manufacturing Expertise Highlighted in Drug Development and Delivery Special Feature on Outsourcing Formulation Development and Manufacturing


    Jul 14, 2022

    Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress and Expo


    For More Press Releases


    Google Analytics Alternative